Fundz Deep Dive
Everything you need to win Kura Oncology — in one platform.
Who to reach, what to say, and why now on Kura Oncology — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Kura Oncology — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Kura Oncology and Kyowa Kirin Collaborate to Develop and Commercialize Ziftomenib for Acute Leukemias
Nov 20, 2024•over 1 year ago
Contract Type
partnership
San DiegoBiotechnology ResearchDescription
Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. have announced a global strategic collaboration to jointly develop and commercialize ziftomenib, with Kura leading the U.S. development and commercial activities while Kyowa Kirin has exclusive commercialization rights outside the U.S
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months